Skip to content
Twitter page opens in new windowLinkedin page opens in new windowInstagram page opens in new window
investorenquiries@pharmaust.com+61 8 9202 6814
PharmAust (PAA)
Cancer Therapeutics Research
PharmAust (PAA)
  • HOME
  • ABOUT
    • Board
    • Corporate Directory
  • PIPELINES & TRIALS
    • Monepantel for Motor Neurone Disease
    • Monepantel for Canine Cancer
    • Veterinary Study Details
    • Monepantel for Human Cancer
    • Publications
  • INVESTOR CENTRE
    • ASX Announcements
    • Annual Reports
    • Investor Presentations
    • PhamAust AGM 2022
    • Company Research
    • Financial Reports
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Podcast Episode 18: Dr Kim Agnew, PharmAust
    • Fireside Chat with Dr Roger Aston
    • Fireside Chat with Dr Kim
    • PharmAust Webinar
    • Epichem Webinar
    • BB PAA Video – September 2021
    • OHD Benchtop Flow Reactor Launch
    • Dr Richard Mollard – Full Interview Ticker TV – 17th June 2020
    • Interview with TechInvest – May 2020
    • Dr. Richard Mollard – 6IX Interview March 2020
    • PharmAust In the News
    • PharmAust Videos
    • PharmAust New Cancer Treatment
    • PharmAust and Catalent Commence GMP Tablet Manufacture (Audio)
    • PharmAust on Youtube
  • CONTACT
  • HOME
  • ABOUT
    • Board
    • Corporate Directory
  • PIPELINES & TRIALS
    • Monepantel for Motor Neurone Disease
    • Monepantel for Canine Cancer
    • Veterinary Study Details
    • Monepantel for Human Cancer
    • Publications
  • INVESTOR CENTRE
    • ASX Announcements
    • Annual Reports
    • Investor Presentations
    • PhamAust AGM 2022
    • Company Research
    • Financial Reports
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Podcast Episode 18: Dr Kim Agnew, PharmAust
    • Fireside Chat with Dr Roger Aston
    • Fireside Chat with Dr Kim
    • PharmAust Webinar
    • Epichem Webinar
    • BB PAA Video – September 2021
    • OHD Benchtop Flow Reactor Launch
    • Dr Richard Mollard – Full Interview Ticker TV – 17th June 2020
    • Interview with TechInvest – May 2020
    • Dr. Richard Mollard – 6IX Interview March 2020
    • PharmAust In the News
    • PharmAust Videos
    • PharmAust New Cancer Treatment
    • PharmAust and Catalent Commence GMP Tablet Manufacture (Audio)
    • PharmAust on Youtube
  • CONTACT

Daily Archives: 26/07/2019

Appendix 3B & s708 Notice

Financial Reports 2019, News & Announcements 2019By PharmAust26/07/2019

190729_Unlisted Options Issuance

July 25 Investor Presentation

Investor Presentations 2019, News & Announcements 2019By PharmAust26/07/2019

190725_PAA PRESENTATION 25 JULY 2019

MENU
  • Home
  • About Us
  • Pipeline & Trials
  • Investor Centre
  • Media
  • Contact Us
SUBSCRIBE TO OUR NEWSLETTER

Facebook
Facebook
fb-share-icon
Twitter
YouTube

PharmAust Follow

PharmAust is a clinical-stage biotech company developing drug discovery IP to treat cancer and neurological diseases. ASX: $PAA FSE: $ECQ

PharmAust
pharmaust PharmAust @pharmaust ·
5 Dec

PharmAust on global pharma radar post-Phase I MND trial; could divest vet program – CEO | ION Analytics | @Mergermarket https://mergermarket.ionanalytics.com/content/1003685710

Reply on Twitter 1732011434392035701 Retweet on Twitter 1732011434392035701 Like on Twitter 1732011434392035701 2 Twitter 1732011434392035701
pharmaust PharmAust @pharmaust ·
4 Dec

PharmAust completes Phase 1 MEND study and files for US Orphan Drug Designation
Via - @PharmaDispatch

Reply on Twitter 1731800187344204140 Retweet on Twitter 1731800187344204140 Like on Twitter 1731800187344204140 8 Twitter 1731800187344204140
Retweet on Twitter PharmAust Retweeted
pharmaust PharmAust @pharmaust ·
1 Dec

Pharmaust completes Phase One Monepantel study and files for Orphan Drug Designation via @themarketherald

Reply on Twitter 1730432667206946849 Retweet on Twitter 1730432667206946849 3 Like on Twitter 1730432667206946849 8 Twitter 1730432667206946849
Load More

Copyright © 2023 PharmAust. All rights reserved.
nil

Website Design & Digital Marketing Perth by Total Click Solutions

Go to Top